Compare SKYX & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYX | ZNTL |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.3M | 118.3M |
| IPO Year | 2022 | 2020 |
| Metric | SKYX | ZNTL |
|---|---|---|
| Price | $2.11 | $1.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $5.00 | ★ $5.87 |
| AVG Volume (30 Days) | ★ 784.8K | 635.4K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $90,751,118.00 | $26,865,000.00 |
| Revenue This Year | $8.81 | N/A |
| Revenue Next Year | $28.17 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.06 | N/A |
| 52 Week Low | $0.88 | $1.01 |
| 52 Week High | $2.20 | $4.00 |
| Indicator | SKYX | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 70.39 | 51.29 |
| Support Level | $1.64 | $1.30 |
| Resistance Level | $2.10 | $1.39 |
| Average True Range (ATR) | 0.17 | 0.08 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 90.91 | 88.10 |
SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.